Quantum BioPharma Ltd
QNTM18.870USD
-1.120-5.60%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
65.45MMarket Cap
LossP/E TTM
More Details of Quantum BioPharma Ltd Company
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Company Info
Ticker SymbolQNTM
Company nameQuantum Biopharma Ltd
IPO dateMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMay 29
Address55 University Ave. , Suite 1003
CityTORONTO
Stock exchangeCanadian Securities Exchange - CSE Listed
CountryCanada
Postal codeM5J 2H7
Phone14168548884
Websitehttps://www.quantumbiopharma.com/
Ticker SymbolQNTM
IPO dateMay 29, 2018
CEODr. Lakshmi P. Kotra, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
--
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Kevin Cassidy
Mr. Kevin Cassidy
Vice President - Quality of Lucid
Vice President - Quality of Lucid
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-100.00%
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+0.25%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
106.76K
--
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+9.30%
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 30
Updated: Sat, Aug 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
27.44%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
Other
62.94%
Shareholders
Shareholders
Proportion
Malone Wealth Ventures LLC
27.44%
Saeed (Zeeshan)
3.10%
Durkacz (Anthony)
2.80%
Carroll (Donal)
2.37%
Lynch (Terrence)
1.35%
Other
62.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.99%
Individual Investor
10.58%
Research Firm
0.49%
Corporation
0.37%
Investment Advisor/Hedge Fund
0.22%
Hedge Fund
0.01%
Other
58.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
2023Q2
52
164.21K
27.10%
+38.85K
2023Q1
56
112.96K
18.07%
-21.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Malone Wealth Ventures LLC
610.37K
20.82%
+610.37K
--
Jun 23, 2025
Saeed (Zeeshan)
118.11K
4.03%
+7.69K
+6.97%
Apr 03, 2025
Durkacz (Anthony)
106.06K
3.62%
+7.69K
+7.82%
Apr 03, 2025
Carroll (Donal)
90.41K
3.08%
+7.69K
+9.30%
Apr 03, 2025
UBS Financial Services, Inc.
1.61K
0.06%
+1.61K
--
Mar 31, 2025
AdvisorShares Investments, LLC
48.99K
1.67%
-283.32K
-85.26%
Mar 31, 2025
Kotra (Lakshmi)
29.57K
1.01%
+7.69K
+35.15%
Apr 03, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
AdvisorShares Psychedelics ETF
9.38%
AdvisorShares Psychedelics ETF
Proportion9.38%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Date
Type
Ratio
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
